Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,734 across all filing types
Latest filing 2021-11-15 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
110年第3季財務報告書 — 202102_1795_AI1.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled '合併財務報告暨會計師核閱報告' which translates to 'Consolidated Financial Report and Accountant's Review Report'. It includes detailed financial statements such as consolidated balance sheets, income statements, cash flow statements, and notes to the financial statements. The report covers the periods ending June 30, 2021 (民國110年) and June 30, 2020 (民國109年). The presence of an accountant's review report (核閱報告) indicates this is a reviewed interim financial report rather than a full audit report or annual report. The reference to International Accounting Standard 34 'Interim Financial Reporting' confirms this is an interim/quarterly report. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q2 2021
2021-11-15 Chinese
110年第3季海外子公司投資
Interim / Quarterly Report Classification · 85% confidence The document contains detailed financial data related to investments in overseas subsidiaries, including shareholding percentages, original investment amounts, investment balances, and recognized investment gains or losses for the current period. The data is presented in a tabular format with notes explaining accounting treatments, indicating substantive financial information rather than a mere announcement or summary. The document length is 1909 characters, which is relatively short but contains actual financial data and analysis. The content aligns with an Interim / Quarterly Report (IR) as it provides financial details for a specific period (110年3季, which corresponds to the third quarter of the 110th year in the Taiwanese calendar). There is no indication that this is an announcement or certification, so it should not be classified as RPA or RNS. Therefore, the most appropriate classification is Interim / Quarterly Report (IR). 9M 2021
2021-11-12 Chinese
110年第3季大陸投資
Regulatory Filings Classification · 90% confidence The document is a detailed tabular disclosure of investment amounts and related financial data concerning investments in mainland China by the company 美時. It includes specific financial figures, investment methods, and regulatory limits. The content is focused on investment details rather than a full financial report or announcement. The document length is short (1439 characters), but it contains substantive financial data related to investments, not just an announcement or certification. This type of disclosure aligns with regulatory filings related to investment disclosures rather than a full annual or interim report. Given the nature and format, it best fits under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2021-11-12 Chinese
本公司將召開線上法人說明會
Investor Presentation Classification · 90% confidence The document is a short announcement (723 characters) about the company 1795 美時 holding an online investor conference call (法人說明會) on a specific date and time. It provides details about the event, including the schedule and access links, but does not contain any financial data or detailed report content. It is clearly an announcement of an upcoming investor presentation rather than the presentation itself or a financial report. According to the classification rules, such announcements about investor presentations are best classified as Investor Presentation (IP) if they contain the presentation itself, but since this is only an announcement of the event, it fits better under Regulatory Filings (RNS) as a general regulatory announcement. However, given the specific nature of the event being an investor presentation, and the document describing the event details, the best fit is Investor Presentation (IP) category, as it is about the investor presentation event. Confidence is high because the document explicitly states it is about a scheduled investor presentation event with detailed timing and access information.
2021-11-11 Chinese
公告本公司董事會通過品質管理副總經理異動案
Board/Management Information Classification · 100% confidence The document is a formal announcement from a listed company (美時) regarding a change in senior management, specifically the retirement and replacement of the Vice President of Quality Management. It includes details such as names, titles, effective dates, and reasons for the change. There is no financial data, report, or presentation content. This fits the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board or senior management.
2021-11-11 Chinese
本公司董事會決議辦理限制員工權利新股收回註銷減資事宜
Share Issue/Capital Change Classification · 95% confidence The document is a regulatory announcement from a listed company (1795 美時) regarding a board resolution to cancel and reduce capital due to the recall of restricted employee shares. It includes details such as the date of the board resolution, amount of capital reduction, number of shares canceled, and other related information. The document is short (808 characters) and is an official announcement of a corporate action related to capital structure changes. It is not a full financial report, audit, or earnings release. The content fits the category of a Share Issue/Capital Change announcement, as it deals with share cancellation and capital reduction.
2021-11-11 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.